Land: Malaysia
Språk: engelska
Källa: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
Etoricoxib
PAHANG PHARMACY SDN. BHD.
Etoricoxib
30 Tablets
MANKIND PHARMA LTD (Unit-II)
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _ BRUTAFLAM Etoricoxib Tablets 60mg, 90mg & 120mg 1 WHAT IS IN THIS LEAFLET? 1. What BRUTAFLAM is used for 2. How BRUTAFLAM works 3. Before you use BRUTAFLAM 4. How to use BRUTAFLAM 5. While you are using it 6. Side effects 7. Storage and Disposal of BRUTAFLAM 8. Product Description 9. Manufacturer and Product Registration Holder 10. Date of revision 11. Serial number 1. WHAT BRUTAFLAM IS USED FOR Your doctor has prescribed Brutaflam tablet for: • treatment of osteoarthritis • treatment of rheumatoid arthritis • treatment of ankylosing spondylitis • treatment of acute pain after minor dental procedures • treatment of menstrual pain • treatment of gout attacks Osteoarthritis is a joint disease. It results from the gradual breakdown of the cartilage that cushions the ends of the bones, resulting in pain, inflammation, tenderness, stiffness, and physical disability. Rheumatoid arthritis is a chronic disease that causes pain, stiffness, swelling and loss of function in the joints and inflammation in other body organs. Ankylosing spondylitis is an inflammatory disease of the spine and large joints. Gout is a disorder characterized by sudden, recurring attacks of pain and inflammation in one or more joints. You may obtain further information from your doctor or pharmacist, who have more detailed information. 2. HOW BRUTAFLAM WORKS It contains a medicine called Etoricoxib. Brutaflam tablet is a member of a group of medicines called selective COX-2 inhibitors that are used to reduce pain and inflammation. Brutaflam tablet is not a narcotic. 3. BEFORE YOU USE BRUTAFLAM - _When you must not use it _ Do not take Brutaflam tablet if you: • are allergic to any of its ingredients. • have had heart failure, a heart attack, bypass surgery, chest pain, narrow or blocked arteries of the extremities, a stroke or mini stroke • have high blood pressure that has not been controlled by treatment If you are not sure, talk to your doctor, nurse or pharmacist before taking Läs hela dokumentet
BRUTAFLAM (ETORICOXIB TABLETS) PRODUCT NAME BRUTAFLAM-60 (Etoricoxib Tablets 60mg) BRUTAFLAM-90 (Etoricoxib Tablets 90mg) BRUTAFLAM-120 (Etoricoxib Tablets 120mg) NAME AND STRENGTH OF ACTIVE SUBSTANCE(S) Each film coated tablet contains 60, 90 or 120 mg of Etoricoxib _List of Excipients _ _Core :_ Calcium Hydrogen Phosphate Anhydrous, Croscarmellose Sodium, Magnesium Stearate, Microcrystalline Cellulose, Hypromellose and Purified Water. _Tablet Coating:_ Hypromellose, Lactose Monohydrate,Titanium Dioxide, Triacetin. The 60 and 120 mg Tablets also contains Indigo Carmine Aluminum Lake and Iron Oxide Yellow. PRODUCT DESCRIPTION Film-coated tablets. BRUTAFLAM-60: Dark-green colored, round shaped, biconvex film coated tablet plain on both sides. BRUTAFLAM-90: White, round shaped, biconvex, bevelled edge, film coated tablet plain on both sides. BRUTAFLAM-120: Pale-green colored, round shaped, biconvex film coated tablet plain on both sides. PHARMACOLOGICAL PROPERTIES _PHARMACODYNAMICS_ Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids, coxibs, ATC code: M01AH05 Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. Etoricoxib is a potent, orally active, highly selective cyclooxygenase-2 (COX-2) inhibitor within and above the clinical dose range. Two isoforms of cyclooxygenase have been identified: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is responsible for prostaglandin-mediated normal physiologic functions such as gastric cytoprotection and platelet aggregation. Inhibition of COX-1 by nonselective NSAIDs has been associated with gastric damage and platelet inhibition. COX-2 has been shown to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. Selective inhibition of COX-2 by etoricoxib decreases these clinical signs and symptoms with decreased GI toxicity and without effects on platelet function. Across clinical pharmacol Läs hela dokumentet